Content about Allegan, Michigan

December 13, 2013

The Irish High Court has approved Perrigo's pending acquisition of Irish drug maker Elan, the companies said Friday.

ALLEGAN, Mich. — The Irish High Court has approved Perrigo's pending acquisition of Irish drug maker Elan, the companies said Friday.

September 20, 2013

Perrigo Co. has hired a former Food and Drug Administration official for its regulatory department, the drug maker said.

ALLEGAN, Mich. — Perrigo Co. has hired a former Food and Drug Administration official for its regulatory department, the drug maker said Friday.

The Allegan, Mich.-based drug maker announced the appointment of Keith Webber as head of regulatory review, a position in which he will start on Oct. 21. Webber previously served as acting director of the FDA's Office of Pharmaceutical Science, part of the Center for Drug Evaluation and Research, which regulates prescription and OTC drugs. He also served as director of the Office of Generic Drugs.

July 29, 2013

U.S.-based drug maker Perrigo Co. will buy Ireland's Elan Corp. for $8.6 billion, the companies said.

ALLEGAN, Mich. — U.S.-based drug maker Perrigo Co. will buy Ireland's Elan Corp. for $8.6 billion, the companies said Monday.

Elan is best known for the multiple sclerosis treatment Tysabri (natalizumab), marketed and distributed by Biogen Idec. Perrigo manufactures various branded and generic prescription and OTC drugs. A previously announced deal, whereby New York-based Royalty Pharma would acquire the Dublin-based drug maker, fell apart last month after Elan shareholders voted in favor of a share-buyback plan.

June 17, 2013

Perrigo Co. will pay up to $129 million to buy Fera Pharmaceuticals' portfolio of ophthalmic products, Perrigo said.

ALLEGAN, Mich. — Perrigo Co. will pay up to $129 million to buy Fera Pharmaceuticals' portfolio of ophthalmic products, Perrigo said Monday.

Perrigo said the acquisition from Locust Valley, N.Y.-based Fera included an upfront payment of $93 million and milestone payments of about $36 million. The products include generic ophthalmic sterile ointments and solutions and generated sales of more than $30 million in 2012.

April 1, 2013

Perrigo Co. has completed its acquisition of a Pennsylvania-based animal health company, the drug maker said.

ALLEGAN, Mich. — Perrigo Co. has completed its acquisition of a Pennsylvania-based animal health company, the drug maker said Monday.

Perrigo announced that it has closed its purchase of Yardley, Pa.-based Velcera for about $160 million. The company makes OTC products for pets, specializing in products traditionally dispensed only by veterinarians. Its products include PetArmor, a flea and tick repellent that had sales of more than $100 million last year.

February 5, 2013

The Food and Drug Administration has approved a testosterone gel product made by Perrigo, the drug maker said.

ALLEGAN, Mich. — The Food and Drug Administration has approved a testosterone gel product made by Perrigo, the drug maker said Tuesday.

Perrigo announced the approval of the testosterone gel in the 1% strength for the treatment of men with low or no testosterone.

The drug is bioequivalent to AbbVie's AndroGel, which has annual sales of about $705 million, according to Symphony Health.

February 4, 2013

Drug maker Perrigo has launched a generic drug for treating problems of the scalp, the company said.

ALLEGAN, Mich. — Drug maker Perrigo has launched a generic drug for treating problems of the scalp, the company said.

Perrigo announced the launch of clobetasol emulsion propionate foam in the 0.05% strength, a generic version of GlaxoSmithKline's Olux-E. The drug is used to treat moderate to severe dermatosis of the scalp.

January 25, 2013

Perrigo Nutritionals is introducing new packaging that the company said would make providing nutrition to infants more convenient.

GEORGIA, Vt. — Perrigo Nutritionals is introducing new packaging that the company said would make providing nutrition to infants more convenient.

December 28, 2012

Solidifying Perrigo’s leadership position in topical foam-based generic prescription pharmaceuticals, the company announced it has signed a definitive merger agreement and completed the acquisition of Cobrek Pharmaceuticals.

ALLEGAN, Mich. — Solidifying Perrigo’s leadership position in topical foam-based generic prescription pharmaceuticals, the company announced it has signed a definitive merger agreement and completed the acquisition of Cobrek Pharmaceuticals, a privately-held, Chicago-based drug development company, for approximately $45 million.

November 28, 2012

The Food and Drug Administration has approved a drug from Perrigo and Cobrek Pharmaceuticals for treating scalp conditions.

ALLEGAN, Mich. — The Food and Drug Administration has approved a drug from Perrigo and Cobrek Pharmaceuticals for treating scalp conditions.

Perrigo said that Cobrek, with which it is partnering, had received approval for betamethasone validate foam in the 0.12% strength. The drug is a generic version of Luxiq foam, made by GlaxoSmithKline subsidiary Stiefel Labs, and is used to treat corticosteroid-responsive skin conditions of the scalp, also known as scalp psoriasis.

The branded version of the drug has annual sales of about $40 million, according to Perrigo.

August 28, 2012

Perrigo and Tris Pharma have launched a private-label version of Delsym extended-release oral liquid suspension containing dextromethorphan polistirex.

ALLEGAN, Mich., and MONMOUTH JUNCTION, N.J. — Perrigo and Tris Pharma have launched a private-label version of Delsym extended-release oral liquid suspension containing dextromethorphan polistirex.

The comapnies said the product, which is indicated for the temporary treatment of cough due to minor throat and bronchial irritation, will be marketed under major U.S. retailer and wholesalers' store brands or own label brands.

June 27, 2012

The Food and Drug Administration has approved an acne treatment made by Perrigo, the drug maker said Wednesday.

ALLEGAN, Mich. — The Food and Drug Administration has approved an acne treatment made by Perrigo, the drug maker said Wednesday.

May 18, 2012

Perrigo on Friday announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug application for lansoprazole capsules in the 15-mg strength.

ALLEGAN, Mich. — Perrigo on Friday announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug application for lansoprazole capsules in the 15-mg strength. The capsules are a generic equivalent of Novartis' Prevacid 24HR capsules.

Sales for Prevacid OTC were approximately $220 million, Perrigo reported.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

April 12, 2012

Perrigo on Thursday announced that it has initiated shipments of its guaifenesin extended-release tablets in the 600-mg strength, a generic version of Mucinex.

ALLEGAN, Mich. — Perrigo on Thursday announced that it has initiated shipments of its guaifenesin extended-release tablets in the 600-mg strength, a generic version of Mucinex.

The company expects to initiate its full-scale over-the-counter launch of the store-brand equivalent to Mucinex in blister packaging to its retail and wholesale customers before the end of its current fiscal year in June.

Mucinex 600-mg tablets has estimated annual sales of approximately $135 million, according to Perrigo.

March 2, 2012

Perrigo announced that it has initiated market launch and made its first shipments of minoxidil 5% foam, which is a generic version of Rogaine 5% foam hair regrowth treatment, to its retail and wholesale customers. Minoxidil 5% foam is marketed under store- or own-label brands.

ALLEGAN, Mich. — Perrigo announced that it has initiated market launch and made its first shipments of minoxidil 5% foam, which is a generic version of Rogaine 5% foam hair regrowth treatment, to its retail and wholesale customers. Minoxidil 5% foam is marketed under store- or own-label brands.

February 14, 2012

Perrigo on Tuesday announced that it has begun shipping Loratadine-D 12-hour extended-release tablets.

ALLEGAN, Mich. — Perrigo on Tuesday announced that it has begun shipping Loratadine-D 12-hour extended-release tablets.

January 13, 2012

Perrigo on Thursday named Bruce Johnson to VP consumer healthcare research and development. Johnson will lead new product development for the supplier in the U.S. market.

ALLEGAN, Mich. — Perrigo on Thursday named Bruce Johnson to VP consumer healthcare research and development. Johnson will lead new product development for the supplier in the U.S. market. 

Johnson joined Perrigo in 2005 and has since played a critical role in the company’s analytical research and development activities for both the U.S. and abroad.

January 9, 2012

Drug maker Perrigo is buying a privately owned distributor of diabetes products, the company said Monday.

ALLEGAN, Mich. — Drug maker Perrigo is buying a privately owned distributor of diabetes products, the company said Monday.

Perrigo announced the $36 million acquisition of Alpharetta, Ga.-based CanAm Care, whose assets include Dex4 hypoglycemia products, insulin delivery syringes and pen needles, lancing, wound care and compression stockings.

January 4, 2012

Perrigo last week announced that it has received final Food and Drug Administration approval for its generic prescription allergy remedy desloratadine 5 mg, the generic equivalent to Schering-Plough's Clarinex.

ALLEGAN, Mich. — Perrigo last week announced that it has received final Food and Drug Administration approval for its generic prescription allergy remedy desloratadine 5 mg, the generic equivalent to Schering-Plough's Clarinex.

Under the terms of a patent-infringement suit settlement, Perrigo can commercially launch its generic desloratadine product July 1. The new product launch may be a prescription or over-the-counter product, depending on its status at the time of launch, Perrigo stated.

November 28, 2011

Perrigo on Monday announced that it received final approval from the Food and Drug Administration for its store-brand version of Mucinex tablets.

ALLEGAN, Mich. — Perrigo on Monday announced that it received final approval from the Food and Drug Administration for its store-brand version of Mucinex tablets.

Perrigo is still in litigation with Reckitt Benckiser involving the introduction of a private-label Mucinex. "Perrigo is working through the litigation and expects to begin shipping this product in our retail and wholesale customers' store brand packaging in the second half of our fiscal year," Perrigo chairman and CEO Joseph Papa said.

November 21, 2011

Perrigo on Monday named Christopher Roop to the post of VP corporate development.

ALLEGAN, Mich. — Perrigo on Monday named Christopher Roop to the post of VP corporate development. In this role, Roop will be responsible for identifying, evaluating and pursuing acquisition targets that complement the company’s strategic growth objectives.

November 15, 2011

Perrigo on Tuesday announced it received Food and Drug Administration clearance to market and distribute infant formula that contains 100% partially hydrolyzed whey protein.

ALLEGAN, Mich. — Perrigo on Tuesday announced it received Food and Drug Administration clearance to market and distribute infant formula that contains 100% partially hydrolyzed whey protein. The store-brand Comfort Care infant formula is designed for babies with fussiness or gas and will be sold as a nutritionally comparable version of Gerber Good Start gentle infant formula at leading retailers in 2012.

Sales of the national brand are estimated to be $55 million for the latest 52-weeks, as measured by SymphonyIRI Group.

November 2, 2011

Drug maker Perrigo has filed for regulatory approval of a generic topical drug for treating testosterone deficiency, prompting a patent infringement suit from the branded version's manufacturer.

ALLEGAN, Mich. — Drug maker Perrigo has filed for regulatory approval of a generic topical drug for treating testosterone deficiency, prompting a patent infringement suit from the branded version's manufacturer.

October 6, 2011

The Food and Drug Administration has granted tentative approval to a drug made by Perrigo for dermatosis of the scalp.

ALLEGAN, Mich. — The Food and Drug Administration has granted tentative approval to a drug made by Perrigo for dermatosis of the scalp.

Perrigo's clobetasol propionate emulsion foam in the 0.05% strength is a generic version of Stiefel Labs' Olux-E Foam. Sales for the branded version of the drug were $40 million during the 12-month period ended in September, according to Wolters Kluwer.

September 12, 2011

Perrigo this summer developed a healthcare professional outreach strategy, educating pediatricians, for example, around the company’s new infants’ and children’s acetaminophen dosing and packaging changes.

ALLEGAN, Mich. — Perrigo this summer developed a healthcare professional outreach strategy, educating pediatricians, for example, around the company’s new infants’ and children’s acetaminophen dosing and packaging changes. It’s the kind of outreach that’s more often associated with an OTC manufacturer supporting a branded product, not the store-brand medicines that Perrigo produces.